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Rett spectrum disorder is a progressive neurological disease and the most common genetic cause of intellectual disability in females.
MECP2 is the major causative gene. In addition, CDKL5 and FOXG1mutations have been reported in Rett patients, especially with
the atypical presentation. Each gene and diﬀerent mutations within each gene contribute to variability in clinical presentation, and
several groups worldwide performed genotype-phenotype correlation studies using cohorts of patients with classic and atypical
forms of Rett spectrum disorder. The Rett Networked Database is a uniﬁed registry of clinical and molecular data of Rett
patients, and it is currently one of the largest Rett registries worldwide with several hundred records provided by Rett expert
clinicians from 13 countries. Collected data revealed that the majority of MECP2-mutated patients present with the classic form,
the majority of CDKL5-mutated patients with the early-onset seizure variant, and the majority of FOXG1-mutated patients with
the congenital form. A computation of severity scores further revealed signiﬁcant diﬀerences between groups of patients and
correlation with mutation types. The highly detailed phenotypic information contained in the Rett Networked Database allows
the grouping of patients presenting speciﬁc clinical and genetic characteristics for studies by the Rett community and beyond.
These data will also serve for the development of clinical trials involving homogeneous groups of patients.
1. Introduction
Rett syndrome (RTT, OMIM 312750) is a severe neurodeve-
lopmental disorder that aﬀects predominantly females with
an incidence of approximately 1 in 10,000 female birthsmainly
caused by mutations in theMECP2 gene located in the X chro-
mosome [1, 2]. Classic RTT is infrequently observed in males
because a deleterious mutation in the only copy ofMECP2 typ-
ically results in severe neonatal encephalopathy and early
lethality [3]. In the classic form, girls with RTT typically exhibit
a relatively normal period of development for the ﬁrst 6-18
months of life followed by a regression phase where patients
lose acquired language andmotor skills and exhibit intellectual
disability and hand stereotypies. The hand stereotypies are typ-
ical in RTT and appear commonly to be continuous, located
predominantly over the anterior body midline [4].
Beyond the classic form of RTT, a number of atypical
forms with diﬀerent degrees of severity have been described:
the Zappella variant (formerly known as the preserved speech
variant) [5, 6], the infantile seizure onset type [7], the congen-
ital form [8], and the “forme fruste” [9]. Besides the MECP2
gene, additional genes have been associated with the RTT phe-
notype. In particular, mutations in CDKL5, located on the X
chromosome, have been reported in the infantile seizure onset
type of RTT, while mutations in FOXG1, located on chromo-
some 14, have been reported in patients with the congenital
presentation. It is still an object of debate if CDKL5 and
FOXG1mutations are responsible for atypical RTT or for a dif-
ferent neurodevelopmental phenotype [10–12].
Diﬀerent RTT databases have been generated in the past
and recent years. Among them are the International Rett Syn-
drome Association (IRSA) North American database and the
InterRett [13, 14]. The Rett Networked Database (RND) is a
registry of clinical and molecular data for patients aﬀected by
RTT and available at https://www.rettdatabasenetwork.org
[15]. Although it was initially targeting the European popula-
tion of patients with RTT, it is now open to countries outside
of Europe. RND records are updated by clinicians with expe-
rience in RTT, limiting potential bias existing when clinical
data are gathered using questionnaires sent out to families
by mail. It is among the largest RTT registries worldwide
with more than 1900 patients on ﬁle, and it is designed to be
an open-access initiative since data can be retrieved directly
through a web-based search engine by interested professionals
upon the submission of a research proposal to the Scientiﬁc
Review Board [15]. The public has access to general informa-
tion and to content description while the individual patient ﬁle
can be granted only upon registration of physicians and clini-
cal researchers in charge of speciﬁc patients.
Here, we describe the ﬁrst 1007 records contained in the
registry and discuss the content of RND on the basis of the
published guidelines for RTT clinical diagnosis [16, 17]. We
analyzed the phenotype of patients with a MECP2, CDKL5,
or FOXG1 mutation to better understand the typical and
atypical forms of RTT and provide information of RTT
cohorts for the development of clinical trials.
2. Materials and Methods
2.1. RND Data. RND contains clinical ﬁles for 1958 patients
aﬀected by classic or atypical RTT (numbers are given as
of March 1, 2017). Clinical data originates from Croatia
(29 patients), Denmark (64 patients), France (252
patients), Hungary (82 patients), India (3 patients), Israel
(93 patients), Italy (605 patients), Romania (15 patients),
Serbia (50 patients), Spain (398 patients), United Kingdom
(255 patients), USA (96 patients), and Russia (16 patients).
Patient clinical and genetic data were provided and
inserted by the expert clinician through direct patients’ eval-
uation, as described in Grillo et al. [15]. The system is able to
collect 309 items (293 clinical and 16 genetic) grouped into
31 domains (30 clinical and 1 genetic). The system is permis-
sive since patients with incomplete data can be inserted and
later updated.
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Data analysis is presented for the ﬁrst 1007 patients aged
over 5 years and for whom a pathogenic mutation inMECP2,
FOXG1, or CDKL5 has been identiﬁed. Enrolled patients
either met the diagnostic criteria for RTT or had a mutation
in MECP2. All participants had complete mutation testing
including MECP2 sequencing and deletion/duplication test-
ing. Clinical diagnosis utilized the 2002 consensus criteria
[12] or the revised diagnostic criteria for RTT published
in 2010 [11]. CDKL5- and FOXG1-mutated patients were
included whenever the diagnosis of RTT was achieved
according to the 2002 consensus criteria or 2010 revised
RTT criteria.
2.2. Data Analysis. Descriptive statistics were used to
summarize the characteristics of the RND dataset. MECP2
mutation types were grouped as Arg106Trp, Arg133Cys,
Thr158Met, Arg306Cys, Arg168∗, Arg255∗, Arg270∗,
Arg294∗, C-terminal deletion, early truncating mutations
(mutations interrupting the MECP2 protein before amino
acid 310), and large deletions. Those not falling in any of
the above listed categories were grouped as “other.” CDKL5
mutation types were clustered on the basis of early truncating
mutations, late truncating mutations, large deletions, and
missense mutations. FOXG1 mutation types were grouped
as early truncating mutations, late truncating mutations,
gene deletions, and missense mutations.
Diﬀerences in clinical characteristics between groups of
patients were tested by Fisher’s exact test or by chi-squared
analysis when the normal approximation was appropriate.
R tool version 3.5.1 was used for statistical analyses, and
P < 0 05 was considered as signiﬁcant.
3. Results
3.1. Overview of RND Data. Among the 1007 RTT patients
analyzed in this study, 806 were classiﬁed as classic, while
the remaining 201 as atypical. Among this latter group,
46 had the congenital form of RTT, 36 patients the
early-onset seizure variant, and 54 the Zappella variant
(formerly known as the preserved speech variant). For the
remaining 65 patients, the type of atypical form was not
speciﬁed. All cases were sporadic except for 2 pairs of sis-
ters and 5 pairs of monozygotic twins aﬀected by RTT
and carrying a MECP2 mutation.
MECP2 was mutated in 949 patients (94.2%), while 32
patients carried a mutation in CDKL5 (3.2%) and 26 patients
in FOXG1 (2.6%).
3.2. Patients Carrying a Mutation in MECP2. Among the 949
MECP2-mutated patients, 804 have a diagnosis of classic
RTT (84.7%), 24 the congenital variant (2.5%), ﬁve the
early-onset seizure variant (0.5%), and 54 the Zappella vari-
ant (5.7%) and the remaining 62 have an atypical form of
RTT not better speciﬁed in categories (6.5%). All mutation
types are present in this population with p.Arg255∗,
p.Thr158Met, and C-terminal deletions being the most fre-
quent mutations despite signiﬁcant diﬀerence between classic
and atypical forms (Table 1).
Criteria for the clinical diagnosis of RTT were last revised
in the RTT Diagnostic Criteria 2010 [11] in order to include a
regression period, partial or complete loss of acquired pur-
poseful hand skills, stereotypic hand movements, partial or
complete loss of acquired spoken language, and gait abnor-
malities. Wemined the RND data in order to investigate their
compliance with the revised diagnostic criteria. Our analysis
showed that, among the patients carrying a mutation in
MECP2, regression occurred in 96.2% of patients, 86.5% lost
or never acquired purposeful hand skills, 68.0% lost most or
all spoken language, 68.1% had stereotypic hand movements,
and 44.5% had gait dyspraxia (Table 2). On the other hand,
the intense eye pointing phenotype of RTT patients is present
in 87.6% of MECP2-positive cases (Table 2), although not
included in the necessary criteria. In our dataset, the support-
ing criteria are present in about half of the patients carrying a
mutation in MECP2 (Table 2).
RND data were further interrogated to deﬁne the most
frequent clinical signs of MECP2 mutation carriers, among
those retrieved in the RND (Table 3). This analysis revealed
that, in addition to the necessary criteria for RTT diagnosis,
a period of regression (96.2%), absence of speech (68.0%), a
deﬁcient sphincter control (88.5%), eye pointing (87.6%),
feeding diﬃculties (85.2%), and a normal head circumference
at birth (74.1%) are the main clinical signs in MECP2-mu-
tated patients (Table 3).
Stereotypes, profound ID, and bruxism were present in
68.1%, 67.8%, and 62.1% of the study group, respectively.
Fewer than one-third (28.0%) had never learned to walk
independently. Epilepsy before 5 years of age was present in
63.0% of patients; in 3.9% of seizures, onset was before 1 year
of age, and seizures were not controlled or barely controlled
by therapy in 21.4% (Table 3).
A severity score was computed for the MECP2-mutated
patients [6]. Although there is wide variability in clinical
severity, there is a clear eﬀect of speciﬁc common MECP2
point mutations on median clinical severity. The cumulative
distribution plots of patients positive for the MECP2 muta-
tions showed that the missense mutation Arg133Cys and late
truncating mutations are associated to the less severe pheno-
type (Figure 1(a)). The missense mutations Arg306, Thr158,
and Arg106 (arginine or threonine can be replaced by any
amino acid) and the early truncating mutation Arg294∗
belong to the intermediate severity phenotype. The remain-
ing early truncating mutations (Arg168∗, Arg255∗, and
Arg270∗) and large deletions are associated with the “most
severe” form of RTT syndrome (Figure 1(a)).
The cohort of MECP2-mutated RTT patients included
also two pairs of sisters carrying the same MECP2 mutation
but with discordant clinical signs: one individual from each
sibling pair could not speak or walk and had a profound
intellectual deﬁcit (classic RTT), while the other individual
could speak and walk and had a moderate intellectual disabil-
ity (Zappella variant). The ﬁve monozygotic twin pairs
reported in RND were much more concordant than the sister
pairs. Among the twin pairs, only two out of ﬁve had an
identical clinical score, indicating that at least at this level
of investigation, they were phenotypically identical. The
remaining three twin pairs diﬀered in speciﬁc ﬁelds such as
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epilepsy and weight (twin pair 1), level of speech and level of
phrases (twin pair 2), or height, age of regression, and volun-
tary hand use (twin pair 3).
3.3. Patients Carrying a Mutation in CDKL5. RND contains
32 records for CDKL5 mutation-positive cases. Thirty-one
patients had a diagnosis of the early-onset seizure variant of
RTT, while one was diagnosed as atypical RTT. The most fre-
quent mutations, representing the 50% of CDKL5-mutated
patients, were truncating mutations (28.1% of late truncating
and 21.9% of early truncating mutations) followed by mis-
sense mutations (31.2%) and large deletion (18.8%). In our
cohort, the majority of patients had a normal head circumfer-
ence at birth (93.8%), a deﬁcient sphincter control (96.0%),
feeding diﬃculties (97.4%), IQ < 40 (100%), and presence of
hand stereotypies (85.7%) and had never spoken (82.6%)
(Table 3).
As for patients withMECP2mutations, it was possible to
compute the total score for the CDKL5-mutated patients.
However, no correlation was observed between type of muta-
tion and clinical severity (data not shown).
3.4. Patients Carrying a Mutation in FOXG1. RND contained
26 records for FOXG1 mutation-positive cases. Twenty-two
patients had the congenital form of RTT, 2 patients had
the classic form, and two patients were classiﬁed as atypi-
cal. The cumulative distribution of the patients positive for
FOXG1 mutations showed a clear trend toward a less
severe phenotype for FOXG1 late truncating mutations
(Figure 1(b)). In our cohort, all patients carrying a FOXG1
mutation had IQ < 40, microcephaly, and no speech at
examination (Table 3).
3.5. Comparison among the Three Groups. Epilepsy before
5 years of age was statistically signiﬁcant among groups of
patients (p value 0.0001 MECP2 vs. CDKL5 and p
value< 0.044 MECP2 vs. FOXG1), since it was present in
63% of MECP2-mutated patients, in 96.9% (31 out of 32) of
CDKL5 cases, and in 87.5% of FOXG1-mutated patients.
The epilepsy that started before 1 year of age was present in
96.9% of CDKL5 patients with epilepsy, versus 3.9% of
MECP2-mutated patients and 37.5% of FOXG1-mutated
Table 1:MECP2 patients classiﬁed as classic or atypical RTT according to the mutation types reported in RND (total number of patients 949).
Mutation type
Total (%)
(n = 949)
Classic RTT N (%)
(n = 804)
Atypical RTT N (%)
(n = 145) p value classic vs. atypical RTT
p.Arg106Trp 31 (3.3) 26 (83.9) 5 (16.1) 0.894
p.Arg133Cys 62 (6.5) 37 (59.7) 25 (40.3) <0.0001
p.Thr158Met 102 (10.8) 91 (89.2) 11 (10.8) 0.182
p.Arg168∗ 80 (8.4) 74 (92.5) 6 (7.5) 0.043
p.Arg255∗ 106 (11.2) 96 (90.6) 10 (9.4) 0.076
p.Arg270∗ 62 (6.5) 57 (91.9) 5 (8.1) 0.102
p.Arg294∗ 63 (6.6) 59 (93.7) 4 (6.3) 0.041
p.Arg306Cys 67 (7.1) 58 (86.6) 9 (13.4) 0.663
C-Terminal deletion 101 (10.6) 78 (77.2) 23 (22.8) 0.027
Early truncating 93 (9.8) 80 (86) 13 (14) 0.713
Large deletion 72 (7.6) 65 (90.3) 7 (9.7) 0.173
Other 110 (11.6) 83 (75.4) 27 (24.5) 0.004
N: number of cases for which the corresponding item is present; percentage is provided in brackets; the p value of signiﬁcance is provided for comparison.
Table 2: Compliance of the RND data with the revised diagnostic
criteria [11] for patients positive for a mutation in MECP2.
Peripheral vasomotor disturbances are accounted for in the “small
cold hands and feet” score. The item “diminished response to
pain” is not present in RND data.
Clinical sign N N+ (%)
A period of regression 743 715 (96.2)
Necessary criteria
Partial or complete loss of acquired purposeful
hand skills
743 673 (86.5)
Stereotypic hand movements 880 599 (68.1)
Partial or complete loss of acquired spoken
language
754 513 (68.0)
Gait abnormalities 821 365 (44.5)
Supportive criteria
Breathing disturbances when awake 824 441 (53.5)
Bruxism when awake 829 515 (62.1)
Impaired sleep pattern 926 419 (45.2)
Abnormal muscle tone — —
Peripheral vasomotor disturbances — —
Scoliosis or kyphosis 853 444 (52.1)
Growth retardation∗ 771 419 (54.3)
Small cold hands and feet 160 81 (50.6)
Inappropriate laughing or screaming spells 560 171 (30.5)
Diminished response to pain — —
Eye pointing 958 843 (88.0)
N represents the number of cases for which the corresponding item is
present in the patient ﬁle; N+ represents the number of cases positive for
the clinical signs, and the percentage is provided in brackets. ∗Growth
retardation was considered to be present when the weight was below the
25th percentile. When height is considered, 54.3% of MECP2-positive
patients are below the 25th percentile.
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patients. Epilepsy was not controlled by therapy in 84% of
CDKL5-mutated cases versus 21.4% of MECP2-mutated
patients and 58.8% of FOXG1-mutated patients (Table 3).
Breathing dysfunction and eye pointing were statistically
more frequent in MECP2 patients (53.5% and 87.6%,
respectively) rather than in CDKL5 (11.5% and 40.6%,
respectively) or FOXG1 (28% and 13.3%, respectively)
patients (Table 3). Conversely, motor and verbal disabilities
were more severe in CDKL5 and FOXG1 patients rather
than in MECP2-mutated patients. About 92.3% of patients
carrying a FOXG1 mutation had never spoken compared
to the 59% of MECP2 and 82.6% of CDKL5-mutated
patients. Moreover, FOXG1-mutated patients had never
learned to sit (78.3%) and walk (91.3%) compared to
MECP2 (7.7% and 28.0%, respectively) and CDKL5 (23.1%
and 74.1%, respectively).
Other features such as normal head circumference at
birth, deﬁcient sphincter controls, feeding diﬃculties, height
and weight below the 25th percentile, troubled nighttime
sleeping, and cold extremities were very similar among the
three groups of patients carrying a MECP2, CDKL5, or
FOXG1 mutation (Table 3).
The overall cumulative distribution plot of patients
carrying a mutation in theMECP2, CDKL5, or FOXG1 genes
is illustrated in Figure 2. FOXG1 mutations confer the high-
est severity score, followed by CDKL5mutations. The major-
ity of MECP2 mutations are associated with the lowest
severity score.
4. Discussion
Globally, the majority of RND patients do fulﬁll the neces-
sary criteria for the diagnosis of RTT, according to the
revised criteria [16]. A period of regression followed by
recovery or stabilization, representing a required criterion
for a diagnosis of RTT, is recorded in 96.2% of cases. The lack
of recorded regression in nearly 4% of patients is probably
due to the fact that in atypical RTT, especially in the congen-
ital and early-onset seizure variants, the onset of neurological
signs occurs in the ﬁrst months of life, and in these cases, the
regression is more diﬃcult to ascertain.
Interestingly, although loss of acquired speech is included
among RTT diagnostic criteria, RND data show that the
majority of MECP2-positive cases have never spoken (59%),
Table 3: Main clinical characteristics in patients positive for a mutation inMECP2, CDKL5, and FOXG1. Clinical characteristics are listed in
descending order of percentage of patients harboring a mutation in MECP2.
Clinical sign
MECP2
(N = 949)
CDKL5
(N = 32)
FOXG1
(N = 26)
p value
MECP2 vs.
CDKL5
p value
MECP2 vs.
FOXG1
p value
CDKL5 vs.
FOXG1N N+ (%) N N+ (%) N N+ (%)
A period of regression 743 715 (96.2) 16 12 (75.0) 25 13 (52.0) <0.0001 0.140 <0.0001
Normal head circumference at birth 769 570 (74.1) 32 30 (93.8) 17 14 (82.4) 0.012 0.447 0.210
Deﬁcient sphincter control 736 651 (88.5) 25 24 (96.0) 23 22 (95.7) 0.241 0.283 0.952
Eye pointing 880 771 (87.6) 32 13 (40.6) 15 2 (13.3) <0.0001 <0.0001 0.052
Feeding diﬃculties 813 693 (85.2) 38 37 (97.4) 15 13 (86.7) 0.0364 0.877 0.128
Presence of hand stereotypies 880 599 (68.1) 28 24 (85.7) 24 23 (95.8) 0.048 0.004 0.217
IQ < 40 704 477 (67.8) 19 19 (100) 24 24 (100) 0.003 0.0008 1
Microcephaly or deceleration of head growth 771 419 (54.3) 27 12 (44.4) 26 26 (100) 0.310 <0.0001 <0.0001
Gait dyspraxia 821 365 (44.5) 27 20 (74.1) 21 2 (9.5) 0.002 0.001 <0.0001
No speech at examination 754 513 (68.0) 23 21 (91.3) 24 24 (100) 0.018 0.0009 0.140
Epilepsy before 5 years of age 548 345 (63.0) 32 31 (96.9) 16 14 (87.5) 0.0001 0.044 0.206
Scoliosis 853 444 (52.1) 24 2 (8.3) 22 6 (27.3) <0.0001 0.022 0.091
Bruxism 829 515 (62.1) 32 14 (43.8) 17 11 (64.7) 0.036 0.828 0.163
Height below the 25th percentile 767 447 (58.3) 27 13 (48.1) 25 17 (68.0) 0.295 0.332 0.148
Cold extremities 160 81 (50.6) 3 1 (33.3) 22 10 (45.5) 0.553 0.649 0.692
Weight below the 25th percentile 771 419 (54.3) 24 10 (41.7) 25 17 (68.0) 0.220 0.177 0.064
Has never spoken 754 445 (59.0) 23 19 (82.6) 26 24 (92.3) 0.023 0.0007 0.301
Gastrointestinal disturbances 603 261 (43.3) 26 10 (38.5) 22 16 (72.7) 0.627 0.006 0.018
Breathing dysfunction 824 441 (53.5) 26 3 (11.5) 25 7 (28.0) <0.0001 0.012 0.139
Troubled night time sleeping 926 431 (46.6) 32 14 (43.8) 18 11 (61.1) 0.756 0.220 0.239
Never learned to walk 821 230 (28.0) 27 20 (74.1) 23 21 (91.3) <0.0001 <0.0001 0.114
Epilepsy not controlled by therapy 548 117 (21.4) 25 21 (84.0) 17 10 (58.8) <0.0001 0.0003 0.069
Never learned to sit 664 51 (7.7) 26 6 (23.1) 23 18 (78.3) 0.005 <0.0001 0.0001
Epilepsy before 1 year of age 689 27 (3.9) 32 31 (96.9) 16 6 (37.5) <0.0001 <0.0001 <0.0001
N represents the number of cases for which the corresponding item is present in the patient ﬁle; N+ represents the number of cases positive for the clinical sign,
and the percentage is provided in brackets; the p value of signiﬁcance is provided for comparison.
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as reported in Table 3. Notably, hand stereotypies, although
considered an invariant clinical sign of classic RTT, are
absent in 31.9% of MECP2-mutated patients included in
the RND dataset. It is however known that behind midline
and exuberant hand stereotypies, many patients withMECP2
may show more varied stereotypies or subtle stereotypes, like
pill rolling or tapping [18]. Interestingly, although 85.2% of
the MECP2-positive patients have feeding diﬃculties, only
43.3% have gastrointestinal disturbances. This would suggest
that part of the feeding diﬃculties arise from abnormal mus-
cle tone and oropharyngeal dysfunction [19]. Even though
breathing mechanisms in RTT preclinical models have been
heavily investigated, breathing dysfunction “only” aﬀects
53.5% of the patients carrying a mutation in MECP2
(Table 3). This is in line with a recent paper from the Rett
Syndrome Natural History Study in which 51.6% of parents
reported a history of hyperventilation, 67.1% a history of
breath-holding, and 47.2% a history of air-swallowing during
wakefulness [20].
Two earlier studies of the North American RTT Database
relying on 915 patients with a mutation inMECP2 were pub-
lished [21, 22]. Similar to the Australian database, the data
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Figure 1: (a) Cumulative distribution plots of the patients positive for a MECP2 mutation. Mutations were grouped based on Arg106Trp,
Arg133Cys, Thr158Met, Arg306Cys, Arg168∗, Arg255∗, Arg270∗, Arg294∗, late truncating mutations (LTM), large deletions, and all other
mutations. Early truncating mutations correspond to mutations interrupting the protein before amino acid 310. Large deletions
correspond to deletions including either a single exon or the entire gene. (b) Cumulative distribution of the patients positive for a FOXG1
mutation. Mutations were grouped as early truncating mutations (mutations interrupting protein before amino acid 275), late truncating
mutations, gene deletions (deletions involving either single exons or the entire gene), and missense mutations.
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relies on questionnaires sent out to families, and even if the
questionnaires were analyzed by experienced clinicians, the
patients were not all directly examined by the contributors.
Available results mainly concern molecular data with the
distribution and nature of reported mutations. It does not
contain CDKL5 or FOXG1 molecular data and does not pro-
vide details concerning the major phenotypic traits present
in the studied population. In Kirby et al., 87.4% of patients
withMECP2mutation have the typical form and 10.3% have
the atypical form of RTT [22]. Similarly, the percentage of
typical RTT patients with a MECP2 mutation in the RND
is 84.7%. The cumulative distribution showed that there is
a wide clinical variability within the same MECP2 mutation
(Figure 1(a)). However, in accordance with previous reports
[23, 24], the “mildest”mutations areArg133Cys and late trun-
cating mutations. The missense mutations Arg306, Thr158,
and Arg106 (arginine or threonine can be replaced by any
amino acid) and the early truncating mutation Arg294∗
belong to the intermediate severity phenotype. The remain-
ing early truncating mutations (Arg168∗, Arg255∗, and
Arg270∗) and large deletions are among the “most severe”
form of RTT syndrome (Figure 1(a)). It is interesting to note
that the plot of each mutation is not always parallel. For
example, Thr158Met and Arg294∗ move more vertically,
suggesting that the phenotype of patients who have these
mutations is less inﬂuenced by other genetic or environmen-
tal factors.
Interestingly, the cohort of MECP2-mutated RTT
patients included two pairs of sisters carrying the same
MECP2 mutation but with discordant clinical signs. One
individual from each pair could not speak or walk and had
a profound intellectual deﬁcit (classic RTT), while the other
individual could speak and walk and had a moderate intellec-
tual disability (Zappella variant) [25].
The phenotype of the patients carrying a mutation in
CDKL5 and classiﬁed as having atypical RTT is much less
documented than the classic RTT phenotype caused by
MECP2 mutations. A report in 2013 described 86 patients
with a mutation in CDKL5 with data originating from family
questionnaires recorded in InterRett [26], and more recently,
epilepsy and vagus nerve stimulation was studied in a cohort
of 172 cases with a pathogenic CDKL5 mutation [27]. RND
provided information in a cohort of 32 patients harboring a
mutation in CDKL5. Expectedly, for the early seizure variant
of RTT caused by CDKL5mutations, the majority of patients
experienced at least one episode of epilepsy (>90% in all three
cohorts). The proportion of patients with a mutation in
CDKL5 that never learned to walk in the three cohorts is also
very similar (67.4% in InterRett, 64.6% in the International
CDKL5 Disorder Database, and 74.1% in RND), together
with the proportion of patients displaying hand stereotypies
(80.3% of females in InterRett and 85.72% of patients positive
for a mutation in CDKL5 in RND) [26, 27]. There is a diﬀer-
ence between the two cohorts concerning the speech skills,
since 30 out of 76 females (39.5%) with CDKL5 mutation
acquired early speech skills in the InterRett cohort and
39/172 (22.7%) had the simplest level of communication in
the International CDKL5 Disorder Database while only
17.4% females harboring a CDKL5 mutation had shown a
somewhat level of speech in RND [26, 27].
Regarding CDKL5-mutated patients, no signiﬁcant
genotype-phenotype correlation was observed. The pheno-
type of the patients carrying a mutation in FOXG1 and clas-
siﬁed as having atypical RTT is even less documented than
the phenotype caused by CDKL5 mutations. The cumulative
distribution in Figure 1(b) shows a clear trend toward a less
severe phenotype for FOXG1 late truncating mutations.
The cumulative overall distribution in Figure 2 nicely
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Figure 2: Combined graph illustrating the diﬀerent clinical severities between MECP2-, CDKL5-, and FOXG1-mutated patient.
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illustrates the progressive severity going from MECP2 to
CDKL5 and FOXG1 mutation. CDKL5 patients lie in the
most severe range in comparison to MECP2 patients with
FOXG1 patients even more shifted than CDKL5 patients
towards a worse clinical phenotype and a very minimum
overlap with MECP2 patients.
In conclusion, the Rett Networked Database is a registry
for patients with RTT where clinical data are validated by
experienced clinicians upon direct examination of the
aﬀected individuals. One of the unique features of this data-
base is its ability to collect a huge amount of clinical details,
the collected clinical items being almost 300 with diﬀerent
levels of completeness, and genetic data [10–15]. RND col-
lects data from 13 diﬀerent countries; however, at the
moment, it could not be considered representative of all the
countries from which data is sourced given the diﬀerent
involvement of each country in terms of shared entries. Its
strength is that it contains a large number of cases, thus pro-
viding a powerful resource to perform genotype-phenotype
correlations of RTT patients from European countries and
beyond. Overall, observation of RND data highlights clinical
characteristics which occur more frequently in patients with
a speciﬁc mutation (Table 3). For example, presence of
regression and gait dyspraxia are statistically more frequent
in MECP2-mutated patients; epilepsy and reduction in eye
pointing capability are statistically more frequent in
CDKL5-mutated patients, while the large majority of
FOXG1 patients have never learned to walk, sit, and speak.
Moreover, we observed that the majority of MECP2-mu-
tated patients have the classic form of RTT, the majority of
CDKL5-mutated patients have the early-onset variant, and
the majority of FOXG1-mutated patients have the congenital
form, with some exceptions (Figure 3). RND provides an
open structure, available to all interested professionals, and
a searchable web interface made available for registered
users. These characteristics should prove useful to perform
additional phenotype-genotype correlations, to better
understand the typical and atypical forms of RTT, and to
select adequate patient populations for future clinical trials.
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Figure 3: Genotypes and phenotypes in RND. The majority of MECP2-mutated patients (light blue) have the classic form (triangles), the
majority of CDKL5-mutated patients (green) have the early-onset seizure variant (stars), and the majority of FOXG1-mutated patients
(pink) have the congenital form (crosses). Several exceptions to this rule are present: among the MECP2-mutated patients (light blue),
about 6% has the Zappella variant (dots), about 2.5% has the congenital variant of RTT (crosses), and about 0.5% has the early-onset
seizure variant (stars); among the CDKL5-mutated patients (green), about 3% of the patients has other atypical forms of RTT (dots and
crosses); and among the FOXG1-mutated patients (pink), about 7% of patients has the classic form (triangles).
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